Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-06
1997-08-19
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 21, 424 91, C07K 700, A61K 3809
Patent
active
056588844
ABSTRACT:
A regimen for the therapeutic management of a gonadal-steroid dependent condition in a mammal constitutes reducing the estrogen supply thereof by means of administration of a GnRH antagonist in an amount effective to inhibit proliferation of endometrial tissue without substantially stopping the production of endogenous estrogen. A method of determining whether the reduced estrogen supply in an individual is such that the concentration of estradiol has been suppressed to an optimized level appropriate to the therapeutic management of the gonadal-steroid dependent condition such as endometriosis in that individual by the administration of a GnRH antagonist at a given dosage level involves titering the dosage, e.g., by conducting a progesterone challenge test and optimal regimen doses of a GnRH antagonist.
REFERENCES:
patent: 5340584 (1994-08-01), Spicer et al.
Ortho Pharmaceutical Corporation
The Medical College of Hampton Roads
Touzeau P. Lynn
Tsang Cecilia J.
LandOfFree
Establishment of tonic ovarian estrogen secretion for extended t does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Establishment of tonic ovarian estrogen secretion for extended t, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Establishment of tonic ovarian estrogen secretion for extended t will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1104813